Conclusion
inflammation, KOA
INFLAMMATION, COMPLICATIONS
Translation of this multiple assessment findings proposed that intra-articular transplantation of AD-MSCs alleviates KOA complications due to inflammation modulation and induction of cartilage regeneration. Administration of allogeneic AD-MSCs is safe and improves clinical signs and symptoms. The analyzed end points suggested pinnacle enhancement in WOMAC, VAS, KOOS, and SF-36 after 6 months. For future investigations, clinical trials with large populations, considering repeated booster doses with 6-month intervals, and assessment of more biological markers in synovial fluid following the AD-MSCs transplantation are recommended.